EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression



Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression



Journal of Affective Disorders 76(1-3): 191-200, September



Background: The therapeutic efficacy of adding lithium to an ongoing antidepressant in resistant depression is well known. However there is less data concerning the efficacy of giving lithium and antidepressant concurrently from the start of treatment. Methodology: The primary objective of this study was to compare the efficacy of a combination of clomipramine+lithium (C+L) with that of clomipramine+placebo (C+P) in-patients with unipolar major depression, during the first 11 days of treatment. Secondary objectives were the assessment of effectiveness after 6 weeks and assessment of the safety of the combination clomipramine and lithium carbonate. C+L and C+P groups were compared for 6 weeks in a multicenter randomized trial of 141 patients hospitalized with a DSM-IV diagnosis of major depression. Efficacy was evaluated using the standard MADRS and CGI scales. Results: Analysis of the 'as treatment ITT' population showed: the percentage reduction in MADRS scores between DO and D11 in this population was better in the C+L group but not statistically significant (C+L: 32.1 vs. C+P: 27.4, P=0.07). Nevertheless, the comparison of mean MADRS scores showed a significant difference in the C+L group on days 4 (C+L: 25.1 vs. C+P: 27.8) and 7 (C+L: 18.6 vs. C+P: 21.5), P<0.05, and approaching significance on day 11 (C+L: 14.6 vs. C+P 17.2, P=0.054). On day 7, the number of patients in total remission was threefold higher in the C+L group than in the C+P group (15 vs. 4%, P<0.05) and twofold on day 11 (29 vs. 14%, P<0.05). CGI severity score showed C+L was superior to C+P on days 4, 7 and 11 and CGI improvement score was better in C+L group on day 11 (P<0.05). After 6 weeks of treatment no statistical difference was found between the two groups from the clinical point of view. Safety based upon clinical and laboratory parameters was satisfactory in both groups during the 6 weeks of the study. Limitations: Patients with bipolar disorder, previously treated with clomipramine or with any other mood stabilizers during the previous week; or with suicide attempt during the current episode with a score gtoreq3 for item 10 of the MADRS were excluded from the study. Conclusion: The results of this study suggests that lithium slightly to moderately potentiates antidepressant treatment in unipolar non-refractory patients with severe major depression in the first days of treatment but not as significantly as for the bipolar population.

(PDF 0-2 workdays service: $29.90)

Accession: 035349760

Download citation: RISBibTeXText



Related references

Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. Journal of Affective Disorders 76(1-3): 191-200, 2003

Multicenter double-blind randomized parallel-group clinical trial of effectiveness of the combination clomipramine plus lithium carbonate versus clomipramine plus placebo in the treatment of unipolar major depression. European Neuropsychopharmacology 10(Supplement 3): S249, September, 2000

Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. Applied Animal Behaviour Science 67(4): 255-275, 2000

Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Depression and Anxiety 28(4): 297-302, 2011

Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. Journal of the American Academy of Child & Adolescent Psychiatry 42(1): 22-29, January, 2003

Paroxetine versus clomipramine in adolescents with severe major depression: a double-blind, randomized, multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 42(1): 22-29, 2002

Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry 55(7): 301-305, 1994

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression. Journal of Psychopharmacology 12(3): 273-278, 2000

Efficacy and Safety of On-Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial. Journal of Urology, 2018

Multicenter Double-Blind Study of the Efficacy of Paroxetine versus Clomipramine in Elderly Patients with Major Depression. Journal of Aging & PharmacoTherapy 13(2): 7-19, 2007

Interaction of lithium with 5-HT1B receptors in depressed unipolar patients treated with clomipramine and lithium versus clomipramine and placebo: Preliminary results. Psychiatry Research 111(2-3): 117-124, August 30th, 2002

Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 20(1): 28-37, 2013

Efficacy and safety of oral SK3530 for the treatment of erectile dysfunction in Korean men: a multicenter, randomized, double-blind, placebo-controlled, fixed dose, parallel group clinical trial. Asian Journal of Andrology 10(5): 791-798, 2008

Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study. Journal of Clinical Psychopharmacology 15(4 Suppl 2): 24s-30s, 1995

Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. American Journal of Psychiatry 157(9): 1429-1435, 2000